Pharmacogenomics of serious adverse drug reactions in pediatric oncology

Colin J D Ross, Henk Visscher, S. Rod Rassekh, Lucila I. Castro-Pastrana, Evan Shereck, Bruce Carleton, Michael R. Hayden

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions.

Original languageEnglish (US)
JournalJournal of Population Therapeutics and Clinical Pharmacology
Volume18
Issue number1
StatePublished - 2011
Externally publishedYes

Fingerprint

Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
Pediatrics
Neoplasms
Survivors
Cause of Death
Safety
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Adverse drug reactions
  • Oncology
  • Pediatric
  • Pharmacogenomics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy

Cite this

Ross, C. J. D., Visscher, H., Rod Rassekh, S., Castro-Pastrana, L. I., Shereck, E., Carleton, B., & Hayden, M. R. (2011). Pharmacogenomics of serious adverse drug reactions in pediatric oncology. Journal of Population Therapeutics and Clinical Pharmacology, 18(1).

Pharmacogenomics of serious adverse drug reactions in pediatric oncology. / Ross, Colin J D; Visscher, Henk; Rod Rassekh, S.; Castro-Pastrana, Lucila I.; Shereck, Evan; Carleton, Bruce; Hayden, Michael R.

In: Journal of Population Therapeutics and Clinical Pharmacology, Vol. 18, No. 1, 2011.

Research output: Contribution to journalArticle

Ross, CJD, Visscher, H, Rod Rassekh, S, Castro-Pastrana, LI, Shereck, E, Carleton, B & Hayden, MR 2011, 'Pharmacogenomics of serious adverse drug reactions in pediatric oncology', Journal of Population Therapeutics and Clinical Pharmacology, vol. 18, no. 1.
Ross, Colin J D ; Visscher, Henk ; Rod Rassekh, S. ; Castro-Pastrana, Lucila I. ; Shereck, Evan ; Carleton, Bruce ; Hayden, Michael R. / Pharmacogenomics of serious adverse drug reactions in pediatric oncology. In: Journal of Population Therapeutics and Clinical Pharmacology. 2011 ; Vol. 18, No. 1.
@article{a60997ba2ed14461ba8a36d787a1b77a,
title = "Pharmacogenomics of serious adverse drug reactions in pediatric oncology",
abstract = "Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40{\%} of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions.",
keywords = "Adverse drug reactions, Oncology, Pediatric, Pharmacogenomics",
author = "Ross, {Colin J D} and Henk Visscher and {Rod Rassekh}, S. and Castro-Pastrana, {Lucila I.} and Evan Shereck and Bruce Carleton and Hayden, {Michael R.}",
year = "2011",
language = "English (US)",
volume = "18",
journal = "Journal of Population Therapeutics and Clinical Pharmacology",
issn = "1710-6222",
publisher = "Pulsus Group Inc.",
number = "1",

}

TY - JOUR

T1 - Pharmacogenomics of serious adverse drug reactions in pediatric oncology

AU - Ross, Colin J D

AU - Visscher, Henk

AU - Rod Rassekh, S.

AU - Castro-Pastrana, Lucila I.

AU - Shereck, Evan

AU - Carleton, Bruce

AU - Hayden, Michael R.

PY - 2011

Y1 - 2011

N2 - Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions.

AB - Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions.

KW - Adverse drug reactions

KW - Oncology

KW - Pediatric

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=79959999408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959999408&partnerID=8YFLogxK

M3 - Article

C2 - 21467604

AN - SCOPUS:79959999408

VL - 18

JO - Journal of Population Therapeutics and Clinical Pharmacology

JF - Journal of Population Therapeutics and Clinical Pharmacology

SN - 1710-6222

IS - 1

ER -